Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 18/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.35 |
| ▸ | RELA | Q04206 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5110836 | 0.99 | MRGPRX4 (0.37) | MRGPRX4CYP4F2CYP4A11TP53PKM | |
| SCHEMBL5110696 | 0.92 | CYP4F2 (0.40) | MRGPRX4CYP4F2CYP4A11SMN1; SMN2RAB9A | |
| Hydrochloric Acid SCHEMBL5100251 | 0.92 | ROCK1 (0.38) | MRGPRX4SMN1; SMN2RAB9A | |
| SCHEMBL5109591 | 0.90 | SIRT2 (0.35) | — | |
| SCHEMBL5103500 | 0.88 | NPC1 (0.43) | MRGPRX4TP53SMN1; SMN2RAB9A | |
| SCHEMBL5100446 | 0.83 | IGF1R (0.54) | MRGPRX4RAB9A | |
| Hydrochloric Acid SCHEMBL5110827 | 0.82 | IGF1R (0.53) | MRGPRX4RAB9A | |
| SCHEMBL4007933 | 0.79 | FGFR1 (0.37) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL5096876 | 0.77 | FGFR1 (0.40) | — | |
| SCHEMBL4014149 | 0.74 | FGFR1 (0.51) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | MRGPRX4 131/4885CYP4F2 35/4885CYP4A11 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.